As part of preconceptional obesity management, alongside lifestyle interventions, glucagon-like peptide-1 receptor agonists (GLP-1-RAs)—such as liraglutide and semaglutide—are recommended as the first-line treatment for obese women of reproductive age, provided they are discontinued at least two months prior to conception [2, 16, 18, 52, 105–107]. Here, GLP1R is linked to obesity disorder.